Skip to main content
. 2021 Nov 2;15(1):116–122. doi: 10.1016/j.jiph.2021.10.024

Fig. 1.

Fig. 1

C-reactive protein (CRP) level (mg/dl) before and after receiving therapy (data are expressed as mean ± SE. TCZ-HCQ; tocilizumab plus hydroxychloroquine treatment group, TCZ-RMV; tocilizumab plus remdesivir treatment group.

(*) significantly different when compared with baseline CRP level before receiving TCZ-HCQ at p < 0.001.

(#) significantly different when compared with baseline CRP level before receiving TCZ-RMV at p < 0.001.